Results 161 to 170 of about 4,777,622 (429)

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer

open access: yesInternational Journal of Molecular Sciences, 2018
Esophageal and gastric cancers represent tumors with poor prognosis. Unfortunately, radiotherapy, chemotherapy, and targeted therapy have made only limited progress in recent years in improving the generally disappointing outcome.
D. Vrána   +8 more
semanticscholar   +1 more source

Massage‐Mimicking Nanosheets Mechanically Reorganize Inter‐organelle Contacts to Restore Mitochondrial Functions in Parkinson's Disease

open access: yesAdvanced Science, EarlyView.
Parkinson's disease (PD) progression is aggravated by disrupted inter‐organelle contacts, which are influenced by mechanical forces. NanoMassage, 200 nm PEGylated black phosphorus nanosheets, deliver targeted mechanical stimulation to neural cells.
Tianqi Li   +12 more
wiley   +1 more source

Nurse-led Follow-up and Palliative Care of Esophageal Cancer Patients [PDF]

open access: yes, 2007
Approximately 400,000 patients are annually diagnosed world-wide with esophageal cancer, which makes this malignancy the eight most common cancer (1). The incidence of esophageal cancer has risen remarkably over the past two decades in the Western world,
Verschuur, E.M.L. (Els)
core   +5 more sources

Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy

open access: yesCancer Reports
Background PD‐L1 expression in tumors and immune cells is a biomarker for the efficacy of anti‐PD‐1 antibody (APA) therapy across diverse cancers. Based on the results from the KEYNOTE‐048 trial, pembrolizumab monotherapy is indicated for platinum ...
Akihiro Ohara   +6 more
doaj   +1 more source

Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study

open access: yesFrontiers in Oncology
BackgroundNeoadjuvant therapy is preferentially recommended for resectable locally advanced esophageal malignancies, with patients who achieve pathological complete response (PCR) anticipated to have longer survival rates.
Hai Zhang   +12 more
doaj   +1 more source

A Methodology for Customizing Clinical Tests for Esophageal Cancer based on Patient Preferences [PDF]

open access: yesarXiv, 2016
Tests for Esophageal cancer can be expensive, uncomfortable and can have side effects. For many patients, we can predict non-existence of disease with 100% certainty, just using demographics, lifestyle, and medical history information. Our objective is to devise a general methodology for customizing tests using user preferences so that expensive or ...
arxiv  

Silica and esophageal cancer in Golestan province northeast of Iran [PDF]

open access: yes, 2007
Objectives: Association of silica with diseases like cancers has been determined previously. This study was designed to determine the quantity of silis in flour produced in Golestan province and its relation to the esophageal cancer. Methodology: We took
Besharat, S., Jabbari, A., Semnani, S.
core  

A good start of immunotherapy in esophageal cancer

open access: yesCancer Medicine, 2019
Considering the benefits of immunotherapy in advanced melanoma, non–small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is ...
Qian Zhao, Jinming Yu, Xue Meng
semanticscholar   +1 more source

PPY‐Induced iCAFs Cultivate an Immunosuppressive Microenvironment in Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
Pancreatic ductal adenocarcinoma features abundant stromal components that hinder therapy efficacy. Single‐cell RNA sequencing analysis combined with experiments identified PPY, a gastrointestinal hormone, as a novel inducer of immunosuppressive iCAFs. Mechanistic studies revealed that PPY activates the non‐canonical NF‐κB pathway via EGFR.
Mengdie Cao   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy